NF2-RELATED SCHWANNOMATOSIS
Clinical trials for NF2-RELATED SCHWANNOMATOSIS explained in plain language.
Never miss a new study
Get alerted when new NF2-RELATED SCHWANNOMATOSIS trials appear
Sign up with your email to follow new studies for NF2-RELATED SCHWANNOMATOSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New platform trial takes on NF2 tumors with multiple drug strategies
Disease control Not yet recruitingThis trial tests several drugs in people with NF2-related schwannomatosis, a condition that causes tumors on nerves and in the brain. The study uses a flexible 'platform' design to evaluate treatments for four tumor types: vestibular schwannomas, non-vestibular schwannomas, menin…
Matched conditions: NF2-RELATED SCHWANNOMATOSIS
Phase: PHASE2 • Sponsor: Beijing Tiantan Hospital • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Could a cancer drug shrink brain tumors and save hearing in a rare nerve disorder?
Disease control Not yet recruitingThis trial tests the drug selumetinib in people with NF2-related schwannomatosis, a genetic condition that causes non-cancerous tumors on nerves, often leading to hearing loss. The study includes both adults and children whose tumors cannot be surgically removed or are growing. R…
Matched conditions: NF2-RELATED SCHWANNOMATOSIS
Phase: PHASE2 • Sponsor: Beijing Tiantan Hospital • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Drug combo aims to shrink NF2 tumors and save hearing
Disease control Not yet recruitingThis trial tests whether combining two drugs—luvometinib (a targeted therapy) and serplulimab (an immunotherapy)—can shrink tumors and improve hearing in people with NF2-related schwannomatosis. Participants have progressive vestibular schwannomas or meningiomas that are not suit…
Matched conditions: NF2-RELATED SCHWANNOMATOSIS
Phase: PHASE1, PHASE2 • Sponsor: Beijing Tiantan Hospital • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC